Results 61 to 70 of about 17,859 (212)

PGE2 Desensitizes β-Agonist Effect on Human Lung Fibroblast-Mediated Collagen Gel Contraction through Upregulating PDE4

Mediators of Inflammation, 2013
In the current study, we investigated the effect of a long-acting β-agonist (salmeterol) and a phosphodiesterase 4 (PDE4) inhibitor (cilomilast) on human lung fibroblast-mediated collagen gel contraction.
Qiuhong Fang, Yingmin Ma, Jing Wang, Joel Michalski, Stephen I. Rennard, Xiangde Liu   +5 more
doaj   +1 more source

Bronchodilator reversibility testing in morbidly obese non-smokers: fluticasone/salmeterol efficacy versus salbutamol bronchodilator

BMC Pulmonary Medicine, 2023
A positive response in reversibility testing is widely used to diagnose patients with airway limitations. However, despite its simple procedure, it doesn’t accurately reflect the exact airway irreversibility.
Mona Ibrahim Ahmed, Randa Ibrahim Ahmed, Hasnaa Osama, Amira Karam Khalifa, Abdullah Ali Alshehri, Gaber El-Saber Batiha, Walaa A Negm, Marwa Kamal   +7 more
doaj   +1 more source

Coping with complexity: working beyond the guidelines for patients with multimorbidities [PDF]

, 2015
Primary care physicians believe they are delivering evidence-based care, understanding that adherence to evidence-based clinical guidelines results in tangible benefits in the populations for which they were developed.
Treadwell, Julian
core   +3 more sources

Glucocorticoid Receptor Activation Reprograms NK Cells to Drive AREG‐Mediated Immunosuppression: A Pan‐Cancer Role for AREG

Advanced Science, Volume 13, Issue 2, 9 January 2026.
Natural killer cells, central to anti‐tumor defense, undergo unexpected reprogramming within the tumor microenvironment. Instead of producing IFN‐γ and TNF‐α, they elevate amphiregulin, a tumor‐promoting factor. This shift is linked to glucocorticoid receptor activity and prostaglandin signaling.
Qin Wei, Guirong Liang, Rui zeng, Yuancheng Li, Anlan Hong, Hongsheng Wang, Suying Feng, Yan Wang, Yetao Wang   +8 more
wiley   +1 more source

Combination formoterol and inhaled steroid versus beta(2)-agonist as relief medication for chronic asthma in adults and children (Review) [PDF]

, 2009
Background Formoterol has a fast onset of action and can therefore be used to relieve symptoms of asthma. A combination inhaler can deliver formoterol with different doses of inhaled corticosteroid; when used as a reliever both drugs will be delivered ...
Adams, Balanzat, Berggren, Bisgaard, Bisgaard, Bleecker, Bousquet, British Thoracic Society, Bruce, Buhl, Buhl, Cates, Christopher, Greenstone, Haahtela, Haahtela, Higgins, Higgins, Ind, Johansson, Jonkers, Kuna, Kuna, Lundborg, Ni Chroinin, O'Byrne, O'Byrne, O'Byrne, O'Byrne, O'Byrne, Palmqvist, Price, Price, Rabe, Rabe, Rabe, Richter, Salpeter, Scicchitano, Sears, Sovani, Stallberg, Tattersfield, Tattersfield, Vogelmeier, Vogelmeier, Walters   +46 more
core   +1 more source

Mounier‐Kuhn Syndrome Flare With Pleuritic Chest Pain: A Discussion of Complications and Management

Case Reports in Pulmonology, Volume 2026, Issue 1, 2026.
Background Mounier‐Kuhn syndrome (MKS), or tracheobronchomegaly, is a rare disorder characterized by dilation of the trachea and main bronchi due to atrophy of elastic and smooth muscle fibers. It is associated with recurrent respiratory infections, bronchiectasis, and airway collapse.
Geran Maule, Akil Augustus, Mohammad Khraisat, Jay Mehta, Elio Rodríguez Araque, Michael D. Schweitzer, Tun-Chieh Chen   +6 more
wiley   +1 more source

Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: A one year evaluation of safety and tolerance

Therapeutic Advances in Respiratory Disease, 2008
Introduction: Concerns have been raised regarding the safety of extended use of long-acting β 2-agonists (LABAs). The safety of arformoterol (50 µg QD), and salmeterol (42 µg BID), was assessed over 12 months in subjects with COPD.
J.F. Donohue, N.A. Hanania, K.A. Sciarappa, E. Goodwin, D.R. Grogan, R.A. Baumgartner, J.P. Hanrahan   +6 more
doaj   +1 more source

Efficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: A study level and a patient level network meta-analysis

BMC Pulmonary Medicine, 2012
Background The objective of this study was to evaluate the comparative efficacy of indacaterol 75 μg once daily (OD), tiotropium 18 μg OD, salmeterol 50 μg twice daily (BID), formoterol 12 μg BID, and placebo for the treatment of chronic obstructive ...
Cope Shannon, Zhang Jie, Williams James, Jansen Jeroen P   +3 more
doaj   +1 more source

The once-daily fixed-dose combination of olodaterol and tiotropium in the management of COPD : current evidence and future prospects [PDF]

, 2019
Long-acting bronchodilators are the cornerstone of pharmacologic treatment of chronic obstructive pulmonary disease (COPD). Spiolto (R) or Stiolto (R) is a fixed-dose combination (FDC) containing two long-acting bronchodilators, the long-acting ...
Brusselle, Guy, Derom, Eric, Joos, Guy
core   +1 more source

UV‐Vis Spectrophotometric Determination of Multicomponent Pharmaceuticals: Limitations, Severity‐Driven Strategies, and Method Selection

Journal of Spectroscopy, Volume 2026, Issue 1, 2026.
Multicomponent pharmaceutical products, particularly fixed‐dose combinations (FDCs), have become increasingly important in modern therapeutics to improve patient adherence and therapeutic outcomes. Although chromatographic techniques are widely employed for their analysis, ultraviolet‐visible (UV‐Vis) spectrophotometry remains an attractive alternative
Imad Osman Abu Reid, Sarfaraz Ahmed Mahesar   +1 more
wiley   +1 more source